Search Results - "Yoshikawa, Tomoyuki"

Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis by Suminokura, Jin, Miyamoto, Morikazu, Yoshikawa, Tomoyuki, Kouta, Hiroko, Kikuchi, Yoshihiro, Hada, Taira, Ishibashi, Hiroki, Ito, Tsubasa, Iwahashi, Hideki, Kakimoto, Soichiro, Suzuki, Rie, Matsuura, Hiroko, Kishimoto, Naohisa, Takano, Masashi

“…Bevacizumab (Bev) plays the central role of the adjuvant therapy for patients with ovarian carcinoma. The aim of our study was to examine whether differences…”
Get full text

JAK2/STAT3 pathway as a therapeutic target in ovarian cancers by Yoshikawa, Tomoyuki, Miyamoto, Morikazu, Aoyama, Tadashi, Soyama, Hiroaki, Goto, Tomoko, Hirata, Junko, Suzuki, Ayako, Nagaoka, Isao, Tsuda, Hitoshi, Furuya, Kenichi, Takano, Masashi

“…The activation of JAK2/STAT3 pathway has been reported to have critical roles in several solid tumors. The present study aimed to evaluate the correlation…”
Get full text

Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers by Yoshikawa, Tomoyuki, Takano, Masashi, Miyamoto, Morikazu, Yajima, Isao, Shimizu, Yukihiro, Aizawa, Yusuke, Suguchi, Yuki, Moriiwa, Miki, Aoyama, Tadashi, Soyama, Hiroaki, Goto, Tomoko, Hirata, Junko, Suzuki, Ayako, Sasa, Hidenori, Nagaoka, Isao, Tsuda, Hitoshi, Furuya, Kenichi

“…Purpose Low skeletal muscle mass (sarcopenia) has been reported to have an influence on survival and toxicities of chemotherapy in several solid tumors. The…”
Get full text

Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis by Takasaki, Kazuki, Miyamoto, Morikazu, Takano, Masashi, Soyama, Hiroaki, Aoyama, Tadashi, Matsuura, Hiroko, Kato, Kento, Sakamoto, Takahiro, Kuwahara, Mika, Iwahashi, Hideki, Ishibashi, Hiroki, Yoshikawa, Tomoyuki, Furuya, Kenichi

“…Purpose To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of…”
Get full text

Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas by Miyamoto, Morikazu, Takano, Masashi, Aoyama, Tadashi, Soyama, Hiroaki, Yoshikawa, Tomoyuki, Tsuda, Hitoshi, Furuya, Kenichi

“…Ovarian clear cell carcinoma (CCC) is one of histological subtypes showing poor prognosis due to chemoresistance. The association of autophagy-related proteins…”
Get full text

Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis by Miyamoto, Morikazu, Takano, Masashi, Aoyama, Tadashi, Soyama, Hiroaki, Yoshikawa, Tomoyuki, Tsuda, Hitoshi, Furuya, Kenichi

“…In 2014 World Health Organization criteria, seromucinous carcinoma was defined as a new histological subtype in ovarian carcinomas, but "seromucinous…”
Get full text

Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas by Miyamoto, Morikazu, Takano, Masashi, Tsuda, Hitoshi, Soyama, Hiroaki, Aoyama, Tadashi, Ishibashi, Hiroki, Kato, Kento, Iwahashi, Hideki, Matuura, Hiroko, Yoshikawa, Tomoyuki, Suzuki, Ayako, Hirata, Junko, Furuya, Kenichi

“…Most of the endometrial carcinomas are detected in early stages and have a better prognosis; however, predictive factors for recurrence have not been…”
Get more information

Indispensability of UGT1A16 genotyping in Japanese cancer patients treated with irinotecan by Takano, Masashi, Kato, Masafumi, Yoshikawa, Tomoyuki, Goto, Tomoko, Furuya, Kenichi, Kikuchi, Yoshihiro

Get full text

Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers by Kikuchi, Yoshihiro, Kouta, Hiroko, Asakawa, Takayoshi, Horikoshi, Miyuki, Yoshikawa, Tomoyuki, Takano, Masashi, Furuya, Kenichi

“…Abstract only…”
Get full text

MO10-4 Novel non-invasive biomarkers for the detection of myelofibrosis in patients with myeloproliferative neoplasms by Maekawa, Takaaki, Yoshikawa, Tomoyuki, Moriiwa, Miki, Hirata, Aoi, Shimizu, Yukihiro, Ogata, Hiraku, Saito, Keita, Izumi, Takuya, Nagao, Shigeki, Takano, Kosuke, Okada, Yosuke, Tachi, Noriaki, Teramoto, Masahiro, Kawamura, Toshikuni, Horiuchi, Toshikatsu, Kato, Shoichiro, Kobayashi, Ayako, Kobayashi, Shinichi, Kawaguchi, Hiroyuki, Kimura, Fumihiko

Get full text

Complete remission of patients with heavily pretreated uterine sarcomas by weekly bevacizumab and temozolomide by Takasaki, Kazuki, Ikeda, Sayaka, Matsuura, Hiroko, Kudoh, Kazuya, Yoshikawa, Tomoyuki, Kouta, Hiroko, Takano, Masashi, Kikuchi, Ryoko, Horikoshi, Miyuki, Kikuchi, Yoshihiro

“…Abstract only 11051 Background: Uterine sarcomas are associated with poor prognosis snce the complete remission is extreme rare. Therefore, treatment with…”
Get full text

Effects of bevacizmab, eribulin and oxaliplatin in relapsed patients with platinum-resistant and refractory ovarian carcinomas: A preliminary case series with biomarker evaluation by Suminokura, Jin, Kouta, Hiroko, Kudoh, Kazuya, Horikoshi, Miyuki, Yoshikawa, Tomoyuki, Matsuura, Hiroko, Miyamoto, Morikazu, Takano, Masashi, Kikuchi, Yoshihiro

“…Abstract only e17059 Background: Eribulin is a candidate for paclitaxel-refractory breast cancers, and Bevacizmab (B) is known to enhance efficacy of…”
Get full text

Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition by Miyamoto, Morikazu, Takano, Masashi, Aoyama, Tadashi, Soyama, Hiroaki, Ishibashi, Hiroki, Kato, Kento, Iwahashi, Hideki, Takasaki, Kazuki, Kuwahara, Mika, Matuura, Hiroko, Sakamoto, Takahiro, Yoshikawa, Tomoyuki, Furuya, Kenichi

“…To investigate whether XIAP down-regulation and autophagy inhibition sensitize ovarian clear cell cancer cells to cisplatin. The ovarian clear cancer cell line…”
Get full text

Can serum IL-6 levels predict sarcopenia and poor outcome in relapsed/refractory gynecologic cancer patients? by Yoshikawa, Tomoyuki, Takano, Masashi, Kudoh, Kazuya, Miyamoto, Morikazu, Aoyama, Tadashi, Matsuura, Hiroko, Ishibashi, Hiroki, Iwahashi, Hideki, Kakimoto, Souichirou, Asakawa, Takayoshi, Kouta, Hiroko, Ikeda, Sayaka, Kita, Tsunekazu, Kikuchi, Yoshihiro

“…Abstract only 2592 Background: Cancer cachexia occurs in more than half of cancer patients and can be the primary cause of death for at least 20% of all…”
Get full text

Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial Carcinomas by Miyamoto, Morikazu, Takano, Masashi, Tsuda, Hitoshi, Matuura, Hiroko, Aoyama, Tadashi, Soyama, Hiroaki, Kato, Kento, Iwahashi, Hideki, Ishibashi, Hiroki, Yoshikawa, Tomoyuki, Suzuki, Ayako, Hirata, Junko, Furuya, Kenichi

“…The clinical significance of lymphocyte infiltration (LI) at the invasive front in endometrial carcinomas (EC) has not been determined. The aim of the current…”
Get more information

Effects of nivolumab alone or combination with molecular targeting agents for recurrent and refractory endometrial cancers with biomarker analyses by Takano, Masashi, Yoshikawa, Tomoyuki, Kouta, Hiroko, Horikoshi, Miyuki, Asakawa, Takayoshi, Kudoh, Kazuya, Kita, Tsunekazu, Miyamoto, Morikazu, Aoyama, Tadashi, Matsuura, Hiroko, Ishibashi, Hiroki, Iwahashi, Hideki, Kakimoto, Souichirou, Ikeda, Sayaka, Takasaki, Kazuki, Suminokura, Jin, Kikuchi, Yoshihiro

“…Abstract only e17124 Background: The immunotherapy drug, nivolumab, is now approved for several metastatic cancers, and has resulted in responses previously…”
Get full text

Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review by Miyamoto, Morikazu, Takano, Masashi, Kuwahara, Mika, Soyama, Hiroaki, Kato, Kento, Matuura, Hiroko, Sakamoto, Takahiro, Takasaki, Kazuki, Aoyama, Tadashi, Yoshikawa, Tomoyuki, Furuya, Kenichi

“…Purpose We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for…”
Get full text

Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma by Matuura, Hiroko, Miyamoto, Morikazu, Takano, Masashi, Soyama, Hiroaki, Aoyama, Tadashi, Yoshikawa, Tomoyuki, Kato, Kento, Sakamoto, Takahiro, Kuwahara, Mika, Takasaki, Kazuki, Ishibashi, Hiroki, Iwahashi, Hideki, Tsuda, Hitoshi, Furuya, Kenichi

“…To determine whether CD44, which is associated with tumor growth and metastasis, is related to carcinogenesis and prognosis in ovarian mucinous carcinomas…”
Get full text

Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement by Takano, Masashi, Kikuchi, Yoshihiro, Kato, Masafumi, Yoshikawa, Tomoyuki, Kita, Tsunekazu

“…Recent reports showed that bevacizumab, a humanized recombinant antibody binding to vascular endothelial growth factor (VEGF), harbored a significant activity…”
Get more information

Psoas muscle index at the fifth lumbar vertebra as a predictor of survival in epithelial ovarian cancers by Yoshikawa, Tomoyuki, Miyamoto, Morikazu, Aoyama, Tadashi, Matsuura, Hiroko, Iwahashi, Hideki, Ishibashi, Hiroki, Kakimoto, Soichiro, Sakamoto, Takahiro, Takasaki, Kazuki, Suminokura, Jin, Tsuda, Hitoshi, Kawaguchi, Hiroyuki, Yoshino, Aihide, Takano, Masashi

“…Almost a quarter of a century has passed since the term sarcopenia was defined. Sarcopenia is recognized as a poor prognostic factor in a variety of cancer…”
Get full text